Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Disease, Sickle Cell Hemoglobin C
Conditions
Keywords
sickle cell disease, hydrxoyurea, mHealth intervention
Brief summary
The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.
Detailed description
Sickle cell disease is the most common genetic disorder in the US, affecting about 100,000 Americans, and about 1 in 400 African American live births, incurring annual health care costs of $335 million. SCD can lead to serious complications including unpredictable, debilitating pain episodes, cardiopulmonary disease, stroke, and long-term end organ damage.These complications lead to significant declines in health-related quality of life (HRQOL) and other patient-reported outcomes (PROs), culminating in early mortality, particularly among AYA. Hydroxyurea (HU), at present, is the main FDA approved medication for SCD that reduces morbidity and mortality, improves HRQoL and lowers healthcare utilization.However, adherence to HU remains suboptimal with only 35-50% of patients achieving high adherence (≥90%), particularly among AYA with SCD. Low HU adherence has been associated with worse health outcomes, poor HRQOL and increased healthcare utilization. Low HU adherence is multifactorial, especially in AYA with other competing priorities and vulnerability in developmental and psychological factors contributing to adherence behavior. AYA have adopted text messaging and smartphone apps at a fast pace, including those who have SCD.Existing evidence indicates that mobile health (mHealth) behavioral interventions are feasible and acceptable with modest efficacy at improving medication adherence and self-management in AYA, including SCD. The specific aim for this study is to test the feasibility and acceptability of the MED-Go app as an mHealth behavioral intervention to improve HU adherence among AYA with SCD.
Interventions
BEHAVIORALMED-Go App
A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Sponsors
Ann & Robert H Lurie Children's Hospital of Chicago
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Age 12-21 years old * Any sickle cell disease genotype * On steady state of hydroxyurea for 2 months * Own of have access to a smartphone during the study period
Exclusion criteria
* Recent hospitalizations within the past 7 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients achieving feasibility criteria of using the MED-Go app | 12 weeks | Feasibility is defined as 70% of participants logging their daily HU 70% of the time over 12 weeks or 59 out of 84 study days. This will be reported as a dichotomous outcome, either yes or no. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Scores of System Usability Scale (SUS) | 12 weeks | App usability questionnaires, numerical values, range 10-50 (higher scores indicating better usability of the app) |
| Hydroxyurea adherence rates | 12 weeks | Adherence rate is defined as number of given HU doses as recorded by the app divided by total number of doses during study period. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSherif M. Badawy, MD, MS
Ann & Robert H Lurie Children's Hospital of Chicago
Outcome results
None listed